Skip to main content

Table 1 Demographic and clinical characteristics of patients with viral pneumonia according to empiric antibacterial therapy

From: Impact of antibacterials on subsequent resistance and clinical outcomes in adult patients with viral pneumonia: an opportunity for stewardship

  Long course Short course Mixed infection
(n = 67) (n = 28) (n = 79)
Age 55 (45–66) 57.5 (45–65) 56 (45–69)
Male 33 (49.3) 15 (53.6) 32 (40.5)
Caucasian 43 (64.2) 17 (60.7) 45 (57.0)
African American 20 (29.9) 7 (25) 30 (38.0)
Weight (kg) 81.3 (65.5–95.3) 74.3 (67.5–104.2) 73.5 (55.1–88.7)*
BMI 27.6 (22.6–35.1) 27.3 (22.7–33.8) 25.8 (20.1–32.0)*
Prior admit within 90 days 2 (3.0) 0 (0) 3 (3.8)
Chronic heart failure 12 (17.9) 6 (21.4) 12 (15.2)
Coronary artery disease 13 (19.4) 4 (14.3) 15 (19.0)
COPD 12 (17.9) 9 (32.1) 16 (20.3)
Diabetes mellitus 25 (37.3) 8 (28.6) 25 (31.6)
Chronic kidney disease 15 (22.4) 5 (17.9) 21 (26.6)
ESRD on hemodialysis 6 (9.0) 0 (0) 7 (8.9)
Cirrhosis 2 (3.0) 0 (0) 1 (1.3)
Human immunodeficiency virus 1 (1.5) 0 (0) 2 (2.5)
Active malignancy 31 (46.3) 11 (39.3) 26 (33.0)
Stem cell transplant 14 (20.9) 5 (17.9) 10 (12.7)
Solid organ transplant 9 (13.4) 2 (7.1) 9 (11.4)
 Lung 4 (6.0) 2 (7.1) 8 (10.1)
 Heart 2 (3.0) 0 (0) 1 (1.3)
 Kidney 3 (4.5) 0 (0) 0 (0)
Immunosuppressive therapy 1 (1.5) 3 (10.7) 8 (10.1)*
Immunocompromised 39 (58.2) 15 (53.6) 44 (55.7)
CCI 4 (3–6) 3 (1–5) 4 (2–6)
Intensive care unit admit 44 (65.7) 17 (60.7) 63 (79.7)
 Oncologya 18 (26.9) 5 (17.9) 16 (20.3)
 Nononcology 26 (38.8) 12 (42.9) 47 (59.5)*
Mechanical ventilation 34 (50.7) 10 (35.7) 53 (67.1)**
 Days 5.9 (3.4–13.7) 3.7 (1.85–27.2) 7.0 (3.3–11.9)*
Central line placed 56 (83.6) 14 (50) 53 (67.1)*
Vasopressor support 14 (20.9) 4 (14.3) 35 (44.3)*,**
 Days 3.55 (1.93–13.1) 2.2 (0.8–10.6) 6.3 (3.4–11.6)
APACHE II score 15 (11–20) 14 (8–17) 19 (14–23)*,**
  1. Data expressed as number (% of total) or median (interquartile range)
  2. aICU admit was determined to be oncology related if the patient fit the study definition for active malignancy
  3. *Statistically significant difference (P <0.05) between long-course and mixed-infection groups
  4. **Statistically significant difference (P <0.05) between short-course and mixed-infection groups
  5. BMI body mass index, CCI Charlson’s comorbidity index, COPD chronic obstructive pulmonary disease, ESRD end-stage renal disease